key: cord-0756738-yaehnsu2
authors: Dewigne, Mathilde; Orte Cano, Carmen; Daoud, Mathieu; del Marmol, Véronique; Benhadou, Farida
title: Low incidence of COVID‐19 in hidradenitis suppurativa: How to interpret it?
date: 2021-11-03
journal: Exp Dermatol
DOI: 10.1111/exd.14475
sha: 274df2b3ae1b40147061c89e0f0b453ab5a3c627
doc_id: 756738
cord_uid: yaehnsu2

nan

Dear Editor,

We read with great interest the publication of Giamarellos-Bourboulis et al. 1 that discussed the anti-COVID-19 measurements for hidradenitis suppurativa (HS). The incidence of COVID-19 in HS patients is low as reported in several retrospective studies. In a cohort of more than 8000 HS patients in the United States, 2 there were 39 cases of COVID-19, eight of these were hospitalized due to respiratory complications and one died in intensive care. Interestingly, the majority of these COVID-19 patients were not treated with systemic therapy for HS and no specific risk factors were identified. Meanwhile, only eight cases of mild COVID-19 occurred in a cohort of 75 Spanish patients 3 and no cases of COVID-19 occurred among a cohort of 96 Italian patients. 4 This prompted us to investigate why the incidence of COVID-19 is so low in the HS population and whether there are any risk factors that could increase susceptibility to COVID-19. We conducted the first monocentric Belgian prospective study to date between the period of March 2020 and February 2021 aiming to characterize patients who will develop COVID-19. Patients were contacted by phone at 3 time points in order to cover the pandemic period (March 2020, October 2020 and February 2021). We collected demographic data and detailed medical history. In order to assess the risk factors more precisely, we added the ISARIC-WHO Forms to collect detailed data on individuals presenting with COVID-19 (https://isaric.org/resea rch/covid -19-clini cal-resea rch-resou rces/covid -19-crf/). One hundred thirty five HS patients were included in the study and the characteristics are summarized in Table 1 . The mean age (mean ± standard deviation) was 39.3 ± 11.8 years with a female predominance (64.4%), and the majority (63.7%) were of North European ethnicity. 69.5% of the patients were smokers while 70.6% were alcohol consumers. The mean body mass index (BMI) was 29 ± 6.9 kg/m 2 . The main comorbidities that we have identified were dyslipidaemia (16.3%), hypertension (10.4%), diabetes (4.4%), metabolic syndrome (4.4%) and ischaemic heart disease (2.2%). The proportion of Hurley stage 1, 2 and 3 was 47.1%, 38.6% and 14.3%, respectively. We assessed the dis- should be maintained during the pandemic periods (Data S1).

We would like to thank Dr Njimi for data management and data analysis and the dermatology department of Erasme Hospital and the patients for their contribution.

None. 

Anti-COVID-19 measurements for hidradenitis suppurativa patients

COVID-19 in patients with hidradenitis suppurativa

Experience in patients with hidradenitis suppurativa and COVID-19 symptoms

Moderateto-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak

Hidradenitis suppurativa and adalimumab in the COVID-19 era